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For many years, the Scientific Division (SD) of the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) has been committed to developing reference 
measurement procedures (RMPs) and reference materials in order to improve 
standardization of laboratory assays and result interpretation on a global basis. These 
activities address the general goal of IFCC to advance the science of laboratory medicine 
worldwide, especially in areas of importance where immediate benefits to clinical outcomes 
may result [1, 2]. In this issue, IFCC-SD reports important achievements of its committees 
(Cs) and working groups (WGs) over the last three years. Cs are theme-oriented, overseeing 
a range of projects within a focussed theme, whereas WGs are task-oriented, covering 
various fields of laboratory medicine. The list of active Cs and WGs in 2016 is shown in 
Table 1. 
A pre-requisite and a major challenge for any scientific activity is the development of an 
agreed universal vocabulary and definitions. For many years, IFCC-SD has been involved in 
promoting the use of international nomenclature within laboratory medicine, through its 
connections with the International Union of Pure and Applied Chemistry (IUPAC) and the 
activities of their Joint Committee on Nomenclature, Properties and Units (C-NPU). A 
prominent output of these joint activities is the "Silver Book" [3]. This book describes the 
global scientific standards that summarize terminology in laboratory medicine. The current 
paper reports the first update of this book in a generation, and underlines the scientific 
background of this document and its relevance to biological nomenclature in the e-health era, 
especially as many laboratory medicine specialists are unaware of its existence.  
Several measurands have been standardized by IFCC-SD over the course of the last few 
decades, providing robust anchors for the routine use of tests by manufacturers and clinical 
laboratories. This has permitted the better use of tests in public health, even though the 
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consequences of standardization in terms of unit use and result expression in clinical 
practice have sometimes been unexpected, as in the case of HbA1c [4]. Careful discussions 
with clinical societies and regulatory authorities are critical in order to avoid unanticipated 
adverse consequences of standardization activities.  
A recent example is the standardization of thyroid function tests. The dedicated committee 
(C-STFT) has been very active in the past few years and has succeeded in standardization 
of free thyroxine (FT4) measurement and harmonization of thyroid stimulating hormone 
(TSH) assays. However, due to the substantial change of reported values for some assays 
following standardization, C-STFT was asked by the Food and Drug Administration (FDA) to 
develop a tool to assess the stability of the new calibration before implementation in the 
market and clinical laboratories. In the paper published here, C-STFT has used two web-
based applications based on instrument-specific moving medians of outpatients results 
("Percentile") and flagging rates ("Flagger") based on data from individual laboratories 
grouped by instrument or assay. They showed that both applications are suitable to 
document the stability of  calibration in the post standardization phase, which is a major goal 
to ensure the long-term robustness of the system [5].  
Another measurand successfully standardized during the last few years with significant 
impact on result expression is carbohydrate-deficient transferrin (CDT), a well-recognized 
marker of alcohol consumption. The paper published in this issue clearly describes the 
different steps of the standardization process : 1 - Definition of the measurand (serum 
disialotransferrin to total transferrin fraction as a percentage) ; 2 - Candidate reference 
method (well-defined HPLC method) ; 3 - Establishment of a network of reference 
laboratories for assigning target values to secondary CDT serum calibrators [6]. This process 
allows the direct comparison of values between methods using a common system of units, 
and provides an important added value for clinicians and patients, especially as this 
parameter is very important in a public health and medico-legal context in some countries.  
Other measurands are making good progress towards standardization, such as HbA2.  HbA2 
is a key parameter for the diagnosis of β-thalassemia, which represents a healthcare burden 
in many parts of the world. Comparability of HbA2 values obtained by different methods is 
critical for the optimal use of absolute cut-off values which may be used for diagnostic 
purposes, which first required the establishment of a RMP. The manuscript published in this 
issue relates the different steps of HbA2 standardization, and illustrates the pitfalls and 
difficulties encountered during such as process [7]. This is a good example of the long and 
complicated journey which may be required to achieve a successful outcome in a 
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standardization process, and illustrates the efforts of IFCC- SD to foster collaborations and 
synergies in order to obtain the desired results. 
Another example of ongoing standardization is the 42 amino-acid form of amyloid β (Aβ1-42) 
in cerebrospinal fluid which has clinical and research utility as a biomarker for Alzheimer's 
disease. Although this peptide has been recognized as highly valuable for the diagnosis of 
Alzheimer's disease together with other markers like total and phosphorylated tau protein, 
commercially available immunoassays suffer from a lack of standardization which leads to 
uncertainly in result interpretation. The working group established by the IFCC-SD (WG-
CSF) has defined two candidate RMPs for the quantification of Aβ1-42 in CSF, based on 
liquid chromatography-tandem mass spectrometry. Both of them have been tested in ring 
trials where commutability studies have been performed, leading to the establishment of 
human CSF pools containing endogenous Aβ1-42 at three concentrations as potential 
certified reference materials (CRMs). The next step will be the validation of a definitive RMP. 
This is thus an story in progress with important steps already accomplished which should 
lead in the near future to the standardization of this measurand [8].  
Other tests already or not yet introduced into routine clinical practice need both preliminary 
analytical studies (validation of assays and harmonization of results) and clinical validation 
(demonstration by clinical studies of the clinical relevance of the assays).  
This is the case for markers of bone turnover. In this field, IFCC has created a joint working 
group with the International Osteoporosis Foundation (IOF), with the objective of studying the 
possibilities for harmonization and clinical use of two bone markers, one marker of formation 
(serum procollagen type I N-propeptide) and one bone resorption marker (serum C-terminal 
telopeptide of type I collagen). The paper presented here shows that available data support 
the potential of these markers to be informative in relation to fracture risk and efficacy of 
osteoporosis treatment, provided harmonization of units for reporting values is achieved [9]. 
This provides a good example of collaboration of IFCC with a clinical society. 
Another recent project of the Scientific Division is the standardization of parathyroid hormone 
(PTH) assays. PTH is used as a surrogate marker to assess skeletal and mineral disorders 
associated with chronic kidney disease and bone mineralisation defects. The paper 
published here underlines the clinical importance and the necessity of improving 
standardization of PTH immunoassays, and details the basis for the development of a RMP 
[10]. 
Autoimmunity is a complex domain recently addressed by the IFCC-SD through the 
establishment of the WG "Harmonization of Autoantibody Tests" (WG-HAT). Autoantibody 
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testing is characterized by a striking lack of comparability of methods, mainly explained by 
the absence of common reference materials, whose availability could considerably improve 
the situation. In cooperation with the Institute for Reference Materials and Measurements 
(IRMM), WG-HAT has developed a CRM for myeloperoxidase-anti-neutrophil cytoplasmic 
antibodies (MPO-ANCA), usable as common calibrant and able to significantly improve the 
comparability of results from commercial immunoassays [11]. This first step will be followed 
by other developments on different antibodies.  
The implementation of new analytical approaches in the clinical laboratory represents a 
recurrent challenge, even when such approaches are well established in the context of 
research or in specialist settings. The example of mass spectrometry is emblematic. This 
methodology has been restricted to the research area for many years, but recently the 
number of applications in the clinical laboratory has expanded considerably for small 
molecules and increasingly for peptides, and it is expected that such methods will become 
routine in the future. Therefore, the establishment of standardized procedures is of 
paramount importance. A review of methodological issues (selection and collection of 
samples, storage stability, preparation, analyte enrichment, trypsin digestion and 
quantification), as well as a review of the different analytical systems suitable for clinical 
mass spectrometry proteomics is provided by the SD-WG on Clinical Quantitative Mass 
Spectrometry Proteomics (WG-cMSP) [12]. This review clearly demonstrates that the control 
of pre-analytical and analytical phases is a major challenge for the development of reference 
methods and the diffusion of good practice in laboratories working routinely with mass 
spectrometry systems.  
Another rapidly expanding field of interest covered by the SD is molecular diagnostics. After 
establishing a network of IFCC-approved reference laboratories, the Committee for 
Molecular Diagnostics (C-MD) has prepared an overview of various technical 
recommendations for the pre-examination phase of laboratory testing in molecular 
diagnostics, extensively referring to the International Organization for Standardization (ISO) 
guidance document ISO 15189. As this document is a general purpose document for 
laboratory medicine, C-MD has selected clinical vignettes illustrating how and why selected 
recommendations for the pre-examination phase might improve patient care for molecular 
diagnostic tests. These examples are drawn from various fields of molecular diagnostics 
including infectious diseases, oncology, inherited diseases and pharmacogenomics, and 
bring together experiences from various countries around the world, demonstrating the global 
nature of the issues [13]. 
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Whatever the tests considered, the establishment of reference intervals is a major goal for 
laboratory medicine. In this regard, the Committee for Reference Intervals and Decision 
Limits (C-RIDL) of the SD has undertaken a global campaign in order to establish reference 
values for a series of common laboratory measurements. Two papers in this issue illustrate 
particular aspects of this multicentre study which has been conducted in 12 countries and 
has targeted 50 analytes. The first paper describes a novel statistical method which may be 
used for establishing reference values, utilising a robust and well-defined mathematical 
model. This study shows that reference intervals for nearly half of the analytes addressed 
showed significant between-country differences [14]. In the second paper, the sources of 
variation in reference values were explored for 13 ethnic groups from 12 countries. The 
major finding was that specific sex and age profiles of reference values were observed for 
the majority of analytes regardless of country.  The close correlation between body mass 
index (BMI) and some reference intervals was notable. However, even though BMI-related 
changes in reference values were identified in all countries, the slope of regression line 
differred greatly across the ethnic groups, demonstrating the importance of taking into 
account several other independent parameters (geographical and ethnic origins, social 
context, lifestyle) when establishing reference intervals [15].  
In conclusion, the manuscripts collected in this special issue highlight the continuous and 
successful efforts of IFCC-SD to achieve standardization or harmonization of laboratory tests 
and to ensure their optimal use in routine clinical laboratory practice. As the need for 
standardization of simple molecules is decreasing, IFCC-SD is committed to the 
standardization of more complex measurands, and will continue to have a leading role in this 
field, in conjunction with relevant partners, to ensure that laboratory medicine makes the 
most positive impact possible to patient care around the world.  
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Committee/Working Group  
 
Chair in 2016 
 
  
Committee on Nomenclature, Properties and Units (C-NPU) R. Flatman (AU) 
 
Committee on Molecular Diagnostics (C-MD) D. Payne (US) 
 
Committee on Reference Systems of Enzymes(C-RSE) F. Ceriotti (IT) 
 
Committee on Traceability in Laboratory Medicine (C-TLM) L. Siekmann (DE) 
 
Committee on Reference Intervals and Decision Limits (C-RIDL) Y. Özarda (TR) 
 
Committee on Standardization of Thyroid Function Tests (C-STFT) L. Thienpont (BE) 
 
Working group on Standardization of Hemoglobin A2 (WG-HbA2 ) R. Paleari (IT) 
 
Working group on Standardization of Carbohydrate-Deficient Transferrin 
(WG-CDT) 
 
J.P.M. Wielders (NL) 
Working group on Standardization of Albumin Assays in Urine (WG-SAU) L.M. Bachmann (US) 
 
Working group on Pregnancy-Associated Plasma Protein A Standardization 
(WG-PAPPA) 
 
S. Wittfoot (UK) 
 
Working group on Growth Hormone (WG-GH) E. Lentjes (NL) 
 
Working group on Standardization of Insulin Assays (WG-SIA) M. Steffes (US) 
 
Working group on Standardization of Troponin I (WG-TNI) D. Bunk (US) 
 
Working group on Harmonization of Autoantibody Tests (WG-HAT)  J. Sheldon (UK) 
 
Working group on Clinical Quantitative Mass Spectrometry Proteomics 
(WG-cMSP) 
 
S. Lehmann (FR) 
Working group on Parathyroid Hormone (WG-PTH) C. Sturgeon (UK) 
 
Working group on Cerebrospinal Fluid Proteins (WG-CSF) K. Blennow (SE) 
 
Working group on Standardization of Bone Markers Assays (WG-BMA) H. Morris (AU) 
  
Working group on Commutability (WG-CM) G. Miller (US) 
 
  
 
 
 
     Table 1 Committees and Working Groups of the IFCC-SD in 2016 
 
 
